Patient characteristic | Non-neutropenic (n = 694) | Neutropenic (n = 100) | p b |
---|---|---|---|
Age | 60 ± 16 | 58 ± 12 | 0.08 |
Male sex | 387 (56Â %) | 66 (66Â %) | 0.06 |
Race | Â | Â | Â |
 White | 380 (55 %) | 73 (73 %) | <0.01 |
 Black | 255 (37 %) | 17 (17 %) |  |
 Asian | 19 (3 %) | 0 (0 %) |  |
 Other/unknown | 40 (6 %) | 10 (10 %) |  |
APACHE III | 74 (59–90) | 87 (71–109) | <0.01 |
Documented bacteremia | 182 (26Â %) | 43 (43Â %) | <0.01 |
Source of infection | Â | Â | Â |
 Pulmonary | 289 (42 %) | 40 (40 %) | 0.05 |
 Genitourinary | 82 (12 %) | 6 (6 %) |  |
 Abdominal/gastrointestinal | 93 (13 %) | 15 (15 %) |  |
 Head/neck | 17 (2 %) | 0 (0 %) |  |
 Bloodc | 58 (8 %) | 15 (15 %) |  |
 Skin/soft tissue/bone | 40 (6 %) | 2 (2 %) |  |
 Gynecologic | 2 (0 %) | 0 (0 %) |  |
 Unclear source | 113 (16 %) | 22 (22 %) |  |
Shock at presentation | 371 (53Â %) | 74 (74Â %) | <0.01 |
Aminoglycoside exposure | 182 (26Â %) | 65 (67Â %) | <0.01 |
IV contrast exposure | 143 (21Â %) | 23 (23Â %) | 0.97 |
ICU admitting source | Â | Â | Â |
 Emergency department | 436 (63 %) | 33 (33 %) | <0.01 |
 Hospital ward | 200 (29 %) | 64 (64 %) |  |
 Other institution | 58 (8 %) | 3 (3 %) |  |
Comorbidities | Â | Â | Â |
 Lymphoma | 45 (6 %) | 13 (13 %) | 0.02 |
 Leukemia | 33 (5 %) | 52 (52 %) | <0.01 |
 Multiple myeloma | 21 (3 %) | 10 (10 %) | <0.01 |
 Solid malignancy | 82 (12 %) | 16 (16 %) | 0.24 |
 Solid organ transplant | 50 (7 %) | 3 (3 %) | 0.08 |
 AIDS | 11 (2 %) | 2 (2 %) | 0.67 |
 Diabetes | 225 (32 %) | 19 (19 %) | <0.01 |
 Chronic renal disease | 119 (17 %) | 9 (9 %) | 0.04 |
 Congestive heart failure | 107 (15 %) | 6 (6 %) | 0.01 |
 Chronic liver disease | 81 (12 %) | 2 (2 %) | <0.01 |
Outcomes | Â | Â | Â |
 ARDSd | 267 (38 %) | 42 (42 %) | 0.51 |
 AKId | 263 (38 %) | 58 (58 %) | <0.01 |
 30-day mortality | 285 (41 %) | 53 (53 %) | 0.02 |
 60-day mortality | 311 (45 %) | 60 (60 %) | <0.01 |